Fortis Healthcare Limited has informed the Exchange about Consideration and recommendation of final dividend of ₹1 per equity share for the financial year 2024-25, subject to approval of the members of the Company.
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare's board, at its May 20, 2025 meeting, approved the audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with statutory auditors B S R & Co. LLP giving an unmodified opinion. The board recommended a final dividend of ₹1 per equity share (10% of face value of ₹10), subject to shareholder approval at the upcoming AGM. On a standalone basis, revenue from operations grew about 22% YoY to ₹144,589 lacs, while EBITDA rose to ₹45,406 lacs from ₹33,581 lacs. However, reported net profit fell sharply to ₹6,379 lacs (from ₹19,945 lacs) and Q4 posted a net loss of ₹4,223 lacs, mainly because of a ₹11,514 lacs exceptional loss from impairment of investments in subsidiaries. The board also appointed Neelam Gupta & Associates as Secretarial Auditor for 5 years and Jitender, Navneet & Co. as Cost Auditor for FY26.
The ₹1 final dividend is the same as last year and represents a very modest yield at current market price, so it is unlikely to move the stock on its own. The sharp drop in headline net profit looks worse than the underlying business, since the fall is driven by a non-cash impairment in subsidiaries, while operating EBITDA actually improved meaningfully. Shareholders should focus on revenue and EBITDA growth rather than the reported profit number.